Skip to content
AdMy Top Trades Now That AI Stocks Are Cratering

Articles

Medtronic (MDT) Upgraded to Overweight by Piper Sandler With $120 Target

Nov 18, 2026 · Trading Tips

Medtronic just picked up a notable vote of confidence from Wall Street. Piper Sandler's Matt O'Brien upgraded the medical device maker to Overweight from Neutral on Tuesday and raised his price target to $120 from $85.

That's a 41% jump in the target. It's also about 16% above where MDT traded Tuesday, near $103.11, which puts the shares close to the top of their 52-week range of $73.31 to $106.33.

O'Brien's argument is that Medtronic has more going for it than the market is giving credit for. He pointed to a collection of growth drivers that he thinks will push sales ahead of Street expectations for years, as Behind the Markets reported in its rundown of Tuesday's rating changes.

Timing is part of the story. Piper says the catalysts should become clearer at Medtronic's investor meeting on Dec. 11, and it expects the shares to move higher in the months ahead, according to TheFly's report on the upgrade.

The firm also built a revenue model that assumes Medtronic can sustain growth above 5% a year through 2030, per Investing.com's coverage. For a company of this size, that's a meaningful acceleration story.

"[T]he aggregation of multiple growth drivers should result in top-line results ahead of the Street in the coming years." — Matt O'Brien, Analyst, Piper Sandler

Now the valuation picture. Medtronic's market value is around $131.9 billion and the trailing price-to-earnings ratio is about 25. That's not cheap for a business that has spent years known as a slow-and-steady compounder.

Wall Street was already friendly. Of 21 firms tracked, 16 rate the stock bullish and none are bearish.

TD Cowen's Joshua Jennings reiterated a Buy with a $110 target on Sept. 30. Piper's call pushes the high end of the range well past that.

Here's the wrinkle. The average analyst target is about $106.19, only roughly 3% above Tuesday's price. Piper's $120 sits well above the pack, so the upgrade is a high-conviction outlier rather than a consensus view.

For MDT holders, the takeaway is that the debate has shifted from "is Medtronic stable?" to "can it grow faster than anyone expects?" That's a better debate to be in, but it also raises the bar the company needs to clear.

The risks are real. The stock is already near its 52-week high, which leaves little cushion if growth drivers arrive slower than Piper hopes. Execution on newer products and swings in broader medtech valuations can also move the shares.

There's also event risk. When an upgrade is tied to an investor meeting, a stock can run into the event on hope.

If management's targets on Dec. 11 fall short of what the bulls have built into their models, the reaction can sting. That cuts both ways, of course: a strong showing could pull more analysts toward Piper's view.

What to watch: the long-term growth targets Medtronic lays out in December, any update to margin goals, and whether other analysts follow Piper's lead by lifting their own targets toward the $110-$120 zone.

It helps to remember what Piper is and isn't saying. The call isn't a bet that Medtronic transforms overnight. It's a view that steady, broad-based growth across several product areas adds up to more than the market currently prices.

On entry, chasing a stock near its 52-week high is rarely the best use of capital. Investors who like the story might build a position gradually, leaving room to add if the shares dip back toward the $95-$100 area before December.

The bottom line: Piper Sandler is betting Medtronic's growth story is bigger than the market thinks, and Dec. 11 is when the company gets to prove it.